Navigation Links
Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
Date:5/9/2011

;

DIFICID™ (fidaxomicin), if approved, will be the first new antibiotic for the treatment of Clostridium difficile infection (CDI) in nearly 30 years. In two Phase 3 trials for the treatment of CDI, fidaxomicin was non-inferior in clinical cure when compared to vancomycin, the only FDA approved product for CDI.  DIFICID also demonstrated superiority to vancomycin in global cure, which is defined as a cure without recurrence, or a sustained cure, through the end of the follow up period. This difference was driven by DIFICID's lower rates of relapse of diarrhea following cessation of the CDI treatment.

About Clostridium difficile Infection (CDI)

Clostridium difficile infection (CDI), commonly referred to as "C. difficile" or "c-diff", has become a significant medical problem in hospitals, long-term care facilities, and in the community and is estimated to afflict more than 700,000 people each year in the U.S.  It is a serious illness resulting from infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.  Patients typically develop CDI from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, thus allowing C. difficile bacteria to flourish and produce toxins.

Current therapeutic options for CDI include the off-label use of metronidazole and oral vancomycin, the latter being the only FDA-approved treatment.  However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence, defined as a relapse or re-establishment of diarrhea, following cessation of the CDI treatment.

Primary risk factors for CDI include broad-spectrum antibiotic use (such as cephalosporins and fluoroquinolones), older age (over 65) and exposure to emerging hyper-virulent strains (BI/
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rhythmia Medical Highlights Studies to be Presented at Heart Rhythm Society 2011 Annual Scientific Session
2. ConvaTec Supported Studies to be Presented at the 24th Annual Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS)
3. New Study Results Presented on Dexlansoprazole and Lansoprazole Effects on Plavix® (clopidogrel bisulfate)
4. Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections
5. REMEDIAL II Results on PLC Systems RenalGuard® to be Presented at ACC 2011s Late Breaking Clinical Trial Session
6. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
7. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
8. Advancements in GYN Oncology; Instrumentation and Techniques to be Presented by Nicholas C. Lambrou, M.D. of Miami
9. Urocidin™ Phase III Clinical Trial Results to be Presented at EAU and AUA Conferences
10. New England Patriots Offensive Line Wins Second Annual Madden Most Valuable Protectors Award Presented by Prilosec OTC®
11. New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... -- Mauna Kea Technologies (Euronext: MKEA, FR0010609263), ... today announced the set-up of an optical biopsy program ... CHU de Grenoble is now the first hospital in ... gastroenterology, interventional pulmonology and urology patients an innovative platform ... thanks to the endomicroscopy technology developed by Mauna Kea ...
(Date:3/31/2015)... N.Y. , March 31, 2015 ... will be featured in the American Medical Group ... ITN Productions. AMGA,s "High Performing Health" ... the challenges facing the nation,s healthcare system in ... Letter is profiled along with other leading organizations ...
(Date:3/31/2015)... Calif. , March 31, 2015  Frequentz Inc., ... has released a white paper to help the pharmaceutical ... 2013 Drug Supply Chain Security Act (DSCSA). The white ... stages of the GS1 EPCIS Standard(s) and ... outlook on the product tracing requirements that need to ...
Breaking Medicine Technology:Grenoble University Hospital First Hospital in France to set up a Multidisciplinary Optical Biopsy Program With the Cellvizio Endomicroscopy Platform 2Grenoble University Hospital First Hospital in France to set up a Multidisciplinary Optical Biopsy Program With the Cellvizio Endomicroscopy Platform 3AMGA's High Performing Health News Program Features The Medical Letter 2Frequentz Releases White Paper Addressing DSCSA's Current & Future Impact 2Frequentz Releases White Paper Addressing DSCSA's Current & Future Impact 3
... Nov. 9, 2011 GenVec, Inc. (Nasdaq: GNVC ) ... 30, 2011.   GenVec reported a net loss of ... 30, 2011 compared to a net loss of $2.4 million ($0.18 ... months ended September 30, 2011, GenVec,s net loss was $4.9 million ...
... Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical ... companion diagnostics, presents the 2011 ,Debiopharm /Valais Award, ... based in Monthey (Valais), that focuses on point-of-care ... on Celiac disease. Debio R.P., the Martigny-based structure ...
Cached Medicine Technology:GenVec Reports Third Quarter 2011 Financial Results 2GenVec Reports Third Quarter 2011 Financial Results 3GenVec Reports Third Quarter 2011 Financial Results 4GenVec Reports Third Quarter 2011 Financial Results 5Augurix Diagnostics Receives the 2011 'Debiopharm /Valais Award' for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease 2Augurix Diagnostics Receives the 2011 'Debiopharm /Valais Award' for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease 3Augurix Diagnostics Receives the 2011 'Debiopharm /Valais Award' for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease 4Augurix Diagnostics Receives the 2011 'Debiopharm /Valais Award' for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease 5Augurix Diagnostics Receives the 2011 'Debiopharm /Valais Award' for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease 6
(Date:4/1/2015)... The term “420” is thought to have ... group of California teenagers would regularly get together after school ... since become a short-hand term for cannabis use – and ... national holiday for the marijuana culture. , To help celebrate ... websites that help bring cannabis businesses and consumers together, has ...
(Date:4/1/2015)... On April 1st, 2015, Dr. Jason Helfrich, co-founder of ... TV to discuss the epidemic known as “Text Neck.” The average ... angle in which it is bent forward, such as when bent ... spine can cause poor posture often times leading to wear and ... spend hours on their cell phone device emailing, keeping up with ...
(Date:4/1/2015)... Oak Brook, IL (PRWEB) April 01, 2015 ... unfortunately benefited greatly from climate change in recent years, ... will develop an allergic reaction if exposed to poison ... as outdoor enthusiasts and families prepare for summer adventures ... of an uncomfortable poison plant reaction is greater than ...
(Date:3/31/2015)... Battle Creek, Michigan (PRWEB) March 31, 2015 ... interview retired NFL All-Pro Lawrence Taylor to discuss the problem ... treatment. Taylor, through his own history of drug abuse and ... rehabilitation process. , Nicknamed “L.T.” by his teammates on the ... by the league due to failed drug tests, yet he ...
(Date:3/31/2015)... 2015 In conjunction with the ... 1-7, the Mesothelioma Applied Research Foundation (Meso Foundation) ... to complement its existing work in mesothelioma research, ... of the Meso Foundation’s mission, we want to ... related to asbestos, including mesothelioma,” said the Meso ...
Breaking Medicine News(10 mins):Health News:The WeedLife Network Marks the Marijuana Culture’s 420 Celebrations by Offering Steep Advertising Discounts 2Health News:The WeedLife Network Marks the Marijuana Culture’s 420 Celebrations by Offering Steep Advertising Discounts 3Health News:Dr. Jason Helfrich, Co-Founder of 100% Chiropractic, is a Guest on Better TV to Discuss “Text Neck” 2Health News:New Ivarest Poison Ivy Itch Spray Provides All-Day Comfort 2Health News:Lawrence Taylor & Per Wickstrom Discuss the Drug Rehabilitation & Recovery Process 2Health News:Mesothelioma Research Organization Announces New Prevention Program 2Health News:Mesothelioma Research Organization Announces New Prevention Program 3
... ... Global Data Synchronization Network to support U.S. healthcare industry goals for standardized product ... , ... N.J. (Vocus) March 24, 2010 -- A new industry report summarizing the experiences ...
... is similar to that seen in 1918, with implications ... (HealthDay News) -- The 2009 H1N1 "swine flu" virus ... in the 20th century, two teams of scientists report. ... seemed to be less affected by H1N1 during the ...
... some patients with operable disease, review finds , WEDNESDAY, ... patients with operable non-small cell lung cancer, say researchers ... of 34 studies involving almost 8,500 patients (and more ... was 64 percent for patients who had chemotherapy and ...
... Flip-flops and sneakers with flexible soles are easier on ... study by Rush University Medical Center has found. And ... key factor in the development of osteoarthritis. The ... Care & Research . "Traditionally, footwear has been engineered ...
... always a good thing for children in developing nations, according ... Economy . The study found that when Colombia,s coffee trade ... coffee-producing counties. When coffee prices spike, workers spend ... that are good for children,s health, the study found. "The ...
... Mellon University in Silicon Valley will host a one-day ... will focus on the role of high-tech communication and ... "We plan to identify mutually beneficial research agendas and ... our campus," said Martin Griss, director of Carnegie Mellon,s ...
Cached Medicine News:Health News:Healthcare Early-Adopters Issue Industry Report for Using Data Synchronization 2Health News:Healthcare Early-Adopters Issue Industry Report for Using Data Synchronization 3Health News:Healthcare Early-Adopters Issue Industry Report for Using Data Synchronization 4Health News:Healthcare Early-Adopters Issue Industry Report for Using Data Synchronization 5Health News:H1N1 Virus Yields Up More Secrets 2Health News:Chemo May Boost Survival After Lung Cancer Surgery 2Health News:Shoes: A treatment for osteoarthritis in the knees? 2Health News:Study: Child health may suffer in strong economy 2
... With Monitoring Lumen., ,Designed for neonatal ... tube incorporates a monitoring lumen within the ... the distal tip. Luer lock connector bonded ... CO2 monitoring, pressure monitoring or syringe irrigation ...
SPIRAL-FLEX® Reinforced Oral/Nasal Uncuffed Endotracheal Tubes...
SHERIDAN PREFORMED™ Endotracheal Tubes are designed to conveniently position the anesthesia circuit out of the surgical field for oral and maxillofacial procedures....
... Close fitting, low pressure cuff., ... by today's healthcare professionals., High level of ... PVC allows the tube to soften at ... and gently cupped to minimize trauma during ...
Medicine Products: